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Eating disorders are common in adolescence, devastating and strongly comorbid with other 3 
psychiatric disorders. Yet, little is known about their etiology to develop effective preventive 4 
measures. 5 
METHODS: 6 
Longitudinal assessments of disordered eating behaviors (DEBs; binge-eating, purging and 7 
dieting) and comorbid psychopathology were measured in 1,386 adolescents from the 8 
IMAGEN study. Development of DEBs and associated mental health problems were 9 
investigated by comparing participants who reported symptoms at ages 16 or 19, but not at 10 
age 14 to asymptomatic controls. Voxel-based morphometry and psychopathological 11 
differences at age 14 were investigated to identify risk factors for the development of DEBs 12 
and associated mental health problems. 13 
RESULTS: 14 
DEBs and depressive symptoms developed together. Emotional and behavioral problems, 15 
including symptoms of attention deficit hyperactivity disorder (ADHD) and conduct disorder 16 
(CD), predated their development. Alterations in fronto-striatal brain areas also predated the 17 
development of DEBs and depressive symptoms. Specifically, development of binge-eating was 18 
predicted by higher grey matter volumes in the right putamen/globus pallidus at age 14. 19 
Conversely, development of purging and depressive symptoms was predicted by lower 20 
 
6 
volumes in the medial orbitofrontal, dorsomedial and dorsolateral prefrontal cortices. Lower 1 
grey matter volumes in the orbitofrontal and anterior cingulate cortices mediated the 2 
relationship between ADHD and CD symptoms and future purging and depressive symptoms.  3 
CONCLUSIONS: 4 
These findings suggest that alterations in frontal brain circuits are part of the shared etiology 5 
between eating disorders, ADHD, CD and depression and highlight the importance of a 6 
transdiagnostic approach to treating these conditions. 7 




Eating disorders (EDs), including anorexia nervosa (AN), bulimia nervosa (BN) and binge eating 2 
disorder (BED), are severe psychiatric disorders that affect up to 15% of young women and 3% 3 
of young men (1). The peak age of onset is from mid adolescence into emerging adulthood 4 
(age 15 to 19), i.e. at a developmentally sensitive time (2). EDs are characterized by disordered 5 
eating behaviors (DEBs), including dietary restriction, binge-eating and purging. Varying 6 
combinations of these DEBs occur in different EDs and across the weight spectrum from 7 
severely underweight to obese. Crucially, subclinical DEBs whose prevalence is particularly high 8 
(14%-22%) (3, 4) in children and adolescents predict development of full-syndrome EDs in later 9 
life (5, 6). Thus, identifying causal risk factors of DEBs and understanding their development is 10 
key to identifying high-risk groups and developing prevention strategies. 11 
 12 
Comorbid disorders are common in EDs. These include mood, anxiety and substance use 13 
disorders, which are common across all EDs (7) and impulse-control disorders like Attention 14 
Deficit Hyperactivity Disorder (ADHD), oppositional-defiant and conduct disorder (CD), which 15 
are prevalent in BN and BED (7, 8). Longitudinal studies have demonstrated that emotional and 16 
behavioral problems, including ADHD (9, 10) and CD symptoms (11) are risk factors of 17 
developing EDs. ADHD in childhood also confers higher risk of developing depression in 18 
adolescence/young adulthood (12, 13), suggesting that EDs and comorbid depression have 19 




EDs are widely accepted as brain-based disorders and neurobiological overlaps between EDs 2 
and addictions have been suggested (14). Neuroimaging studies have revealed structural and 3 
functional brain differences in ED patients compared with recovered patients and healthy 4 
controls. For example, meta-analyses combining adolescent and adult patients’ data revealed 5 
reduced grey and white matter and increased cerebrospinal fluid (CSF) in AN patients 6 
compared with healthy individuals, such differences becoming less pronounced in recovered 7 
patients (15). However, most of these neuroimaging findings focus on AN or are based on small 8 
cross-sectional studies. The few studies comparing BN or BED patients to healthy individuals 9 
found regional volumetric or cortical thickness differences in the orbitofrontal cortex (OFC), 10 
insula, cingulate cortex and several other regions (16-20). Subcortical shape deformations (21) 11 
and white matter microstructure abnormality (22) were also found in BN patients and were 12 
associated with symptom severity.  13 
 14 
Critical questions remain as to whether any abnormalities displayed reflect predisposing risk 15 
factors or a consequence of prolonged eating disturbances. Should predisposing brain 16 
differences exist, it remains to be answered whether EDs and comorbid mental health 17 
problems have common neural underpinnings, and which neural mechanisms mediate the 18 
relationship between psychopathological risk factors and the development of EDs and 19 
comorbid mental health problems. We have recently demonstrated the value of longitudinal 20 
neuroimaging methods by showing that differences in neural responses to inhibitory control 21 
 
9 
can be detected 2 years before the onset of binge-eating or purging behaviors (23). Altogether, 1 
these findings suggest that advances in understanding and prevention of EDs are likely to 2 
benefit from an approach using dimensional and longitudinal assessments of DEBs, focusing 3 
on underlying neurobiological substrates (24). 4 
 5 
Building up on this, here we use the longitudinal design of IMAGEN, a large, prospective cohort 6 
of European adolescents, to investigate early psychopathological and neuroanatomical risk 7 
factors for the development of DEBs and comorbid mental health problems. Hypothesizing 8 
that structural brain alterations underlie shared risk for developing DEBs and comorbid mental 9 
health problems, we performed longitudinal and mediation analyses to lend insight into the 10 
etiology of EDs and evaluate underlying neural mechanisms through which psychopathological 11 
risk factors relate to the development of DEBs and comorbid mental health symptoms.  12 
  13 
 
10 
Methods and Materials 1 
Participants 2 
Questionnaire and neuroimaging data were obtained from IMAGEN – a longitudinal cohort 3 
acquired from 8 study sites in Europe. Each site received approval from their local research 4 
ethics committee. Written assent from the adolescents and written consent from the parents 5 
were obtained prior to participation. See (25) for details of the recruitment and assessment 6 
methods. In this study, we used questionnaire data acquired at ages 14, 16 and 19, and 7 
neuroimaging data acquired at age 14. 8 
 9 
Psychopathological assessments 10 
Eating disorder symptoms: Binge-eating, purging and dieting behaviors were assessed using 11 
the self-reports from the Development and Wellbeing Assessment (DAWBA) (26, 27). We used 12 
binary variables to indicate the presence or absence of binge-eating, purging and dieting 13 
symptoms at each age. A positive response to question 15, related to eating a large amount of 14 
food and losing control over eating was used to indicate the presence of binge-eating. A 15 
positive response to any of 3 questions (1c, 18f and 18g) related to self-induced vomiting or 16 
taking pills/medicines to lose weight was used to indicate the presence of purging behavior. A 17 
score of 3 (answer for ‘a lot’) for any of the 3 questions (question 18a, 18b and 18c) related to 18 
eating less at meals, skipping meals and fasting was used to indicate the presence of dieting 19 
 
11 
behavior. Dieting behaviors were also defined with more relaxed criteria (score ≥ 2), detailed 1 
in the Supplemental Information.  2 
 3 
We categorized participants into groups who developed DEBs over time and those who 4 
remained asymptomatic based on each of the 3 DEBs. The “binge-eating developers” did not 5 
report binge-eating symptoms at age 14 but developed binge-eating symptoms at age 16 or 6 
19. The “non-bingers” did not report binge-eating at any of the 3 ages. In the same manner we 7 
defined “purging developers”, “non-purgers”, “dieting developers” and “non-dieters”. Besides 8 
these, we compared individuals who did not report any DEB at age 14 but reported at least 9 
one DEB at ages 16 or 19 (“any DEB developers”) to individuals without any DEB at any age 10 
(“non-DEB” group). We also defined groups based on Bartholdy et al. (2019) (23) who 11 
combined binge-eating and purging symptoms together. We report these as “binge-eating or 12 
purging (BoP)”, defining developers, maintainers and recoverers based on their longitudinal 13 
development (See Supplemental Methods). 14 
 15 
As expected, these DEB developers and their asymptomatic controls showed significant sex 16 
differences (Supplemental Table S1). To obtain sex-balanced groups of cases and controls, each 17 
developer group and the corresponding asymptomatic group were matched for sex and 18 
acquisition site, by using the propensity score matching method implemented in the Matchit 19 




Emotional and behavioral problems: The Strengths and Difficulties Questionnaire (SDQ) (29) 1 
was used to measure participants’ emotional and behavioral symptoms. We used self-report 2 
scores at age 14 for the following 4 subscales: emotional symptoms, conduct problems (i.e., 3 
CD symptoms), hyperactivity/inattention (i.e., ADHD symptoms) and peer relationship 4 
problems.  5 
 6 
Mental health symptoms: Computer-generated DAWBA diagnoses (DAWBA bands) (30) 7 
derived from the self-report questionnaire were used to measure the severity of 8 
psychopathology-related symptoms at the 3 ages. DAWBA bands comprised up to 6 levels 9 
(from 0 to 5) and indicated the probability of having a disorder (from <0.1% to >70% probability 10 
of DSM-IV based diagnoses). IMAGEN being a normative cohort, we focused on common 11 
mental health problems in our cohort, as defined by prevalence ≥ 5% at age 19 for participants 12 
scoring 3 and above (15%+ risk according to the DAWBA bands) for the disorder. DAWBA bands 13 
for depression and generalized anxiety disorder (GAD) passed this threshold and their 14 
associations with DEBs were investigated. We defined a group of “depression developers” 15 
(N=290) whose depression scores were below 3 at age 14, and above or equal to 3 at ages 16 16 
or 19. This was compared to controls (labeled as “non-depression”, N=857) whose depression 17 
scores were below 3 across the 3 ages. Similarly, we defined “anxiety developers” (N=203) and 18 




Body mass index (BMI) and medication: BMI (kg/m2) at age 14 was derived from height and 1 
weight measurements and transformed to age- and sex-adjusted z-scores based on the Centre 2 
for Disease Control and Prevention Growth Chart (31). A binary variable was created to indicate 3 
whether participants took any prescription medicine in the past 30 days based on the Timeline 4 
Followback Interview (32).  5 
 6 
Structural Magnetic resonance imaging (MRI) acquisition and processing 7 
MRI images were acquired with 3T MRI scanners (Siemens, Philips, General Electric) across all 8 
IMAGEN sites. A 3D magnetization scan based on the ADNI protocols 9 
(http://adni.loni.usc.edu/methods/documents/mri-protocols/) was used to acquire T1-10 
weighted structural images. Quality control was performed through visual inspection to 11 
exclude images with movement artefacts, brace artefacts or field inhomogeneities. Voxel-12 
based morphometry (VBM) analyses were conducted using the VBM8 toolbox 13 
(http://www.neuro.uni-jena.de/vbm/) in SPM8 (https://www.fil.ion.ucl.ac.uk/spm/) to obtain 14 
grey matter volumes (GMVs), as detailed in the Supplemental Information. Intracranial volume 15 
(ICV), estimated in VBM8 by summing up grey matter, white matter and CSF volumes, was used 16 
as a covariate in all the analyses involving GMVs (33). 17 
 18 
Statistical Analyses 19 
DEB development and comorbid mental health symptoms. To investigate if DEBs and mental 20 
health symptoms co-developed, we tested for associations between the development of DEBs 21 
 
14 
and the development of depression and anxiety symptoms while controlling for sex, acquisition 1 
site and depression or anxiety symptoms at age 14. These analyses were performed with the 2 
whole sample (i.e., without matching for sex and acquisition site).  3 
 4 
Emotional and behavioral problems as predictors of DEBs. We investigated whether SDQ 5 
subscales at age 14 could predict DEB development using Firth logistic regression models (34) 6 
controlling for sex and acquisition site. Potentially confounding effects of BMI were tested by 7 
further controlling significant associations for BMI at age 14. The p values were corrected using 8 
the Holm-Bonferroni method. We also investigated whether emotional and behavioral 9 
problems that predicted DEBs also predicted the development of depression and anxiety 10 
symptoms, controlling for depression or anxiety symptoms at age 14, sex and acquisition site. 11 
 12 
Voxel-wise GMV analyses. We investigated whether structural brain differences at age 14 13 
predated the development of DEBs. Generalized linear models (GLM) in SPM12 involved GMVs 14 
as the dependent variable, and the DEB group (developers vs. controls) as an independent 15 
variable. We tested whether shared anatomical differences underlay the development of DEBs 16 
and comorbid mental health problems as follows. First, we investigated voxel-wise GMV 17 
associations with development of depression and anxiety symptoms. We then tested if the 18 
associated brain regions overlapped with those associated with DEB development. We also 19 
investigated voxel-wise GMV associations with each of the 4 SDQ subscales at age 14. Control 20 
variables included in all analyses were sex, acquisition sites and total intracranial volumes (ICV). 21 
 
15 
Depression or anxiety symptoms at age 14 were also included as covariates in analyses 1 
involving development of depression and anxiety. The threshold for all the neuroimaging 2 
analyses was p<0.001 uncorrected at the voxel level, and p<0.05 corrected for family wise error 3 
(FWE) at the cluster level.  4 
 5 
Mediation analyses. We tested whether the brain regions associated with SDQ subscales 6 
mediated the associations between SDQ subscales at age 14 and development of DEBs and 7 
comorbid depression/anxiety symptoms. The brain regions associated with SDQ subscales 8 
were used as ROIs. Control variables included sex, acquisition site and ICV. The mental health 9 
symptom at age 14 was controlled for when investigating the development of 10 
depression/anxiety. The continuous variables were transformed to z-scores. Confidence 11 
intervals for the mediation effect were estimated from 5000 bootstrap samples by using the 12 
PROCESS macro (v3.2, http://processmacro.org) in SPSS (v25, IBM Corporation). 13 




A total of 1594 participants had non-missingness for the SDQ, DEB variables, BMI and 2 
neuroimaging data at age 14. Out of these, 1386 participants had DEB data at age 16 or 19 and 3 
were used to create DEB developer groups. Among the developers for binge-eating (n=115), 4 
purging (n=155), dieting (n=60), BoP (n=204) and any DEB (n = 138), between 60.9% and 79.1% 5 
were female. Taking this into account, case and control groups were matched based on sex 6 
and recruitment site (Supplemental Table S1 & Figure S1) for the analyses. Descriptive statistics 7 
for BMI and psychopathology scores are provided in Supplemental Table S2.  8 
 9 
DEBs co-develop with depression and anxiety symptoms 10 
We first established that DEBs co-developed with depression and anxiety by testing for 11 
associations between the development of DEBs and depression and anxiety symptoms. 12 
Development of DEBs was significantly associated with higher risk of developing depression 13 
and anxiety, after controlling for their levels at age 14 (Supplemental Table S3 and Figure S2).  14 
 15 
Emotional and behavioral problems predict the development of DEBs, depression and anxiety 16 
symptoms 17 
As emotional and behavioral problems are known predictors of eating disorders (9-11), we 18 
analyzed their associations with DEBs. Emotional problems at age 14 were significant 19 
predictors for the development of binge-eating (OR = 1.35, p = 4.4E-03). ADHD symptoms and 20 
 
17 
CD symptoms at age 14 predicted the development of purging (OR = 1.35, p = 1.6E-03 for ADHD 1 
symptoms; OR = 1.43, p = 8.5E-05 for CD symptoms; Table 1) and BoP behaviors (OR = 1.28, p 2 
= 4.7E-03 for ADHD symptoms; OR = 1.40, p = 1.0E-04 for CD symptoms; Supplemental Table 3 
S4). CD symptoms at age 14 also predicted the maintenance of BoP (OR = 1.69, p = 5.8E-04, 4 
Supplemental Table S4) and the development of “any DEB” (OR = 1.36, p = 3.9E-03, 5 
Supplemental Table S5). These associations remained significant after controlling for BMI. 6 
Further analyses of the association with ADHD symptoms indicated that both the hyperactivity-7 
impulsivity and inattention components contributed to the association with future purging 8 
behaviors (OR = 1.33, p = 2.5E-03 and OR = 1.23, p= 0.028 for hyperactivity-impulsivity and 9 
inattention, respectively). A significant predictor for dieting development was found only by 10 
using a more relaxed criterion for dieting (CD symptoms, OR = 1.27, p = 0.013, Supplemental 11 
Results). 12 
 13 
Emotional and behavioral problems at age 14 also predicted the development of depression 14 
and anxiety at later ages (Table 2). More specifically, emotional problems (OR = 1.56, p= 3.7E-15 
04) and ADHD symptoms (OR = 1.24, p = 0.045) predicted the development of anxiety 16 
symptoms (controlling for depressive symptoms at ages 14, 16 and 19), while CD symptoms 17 
specifically predicted the development of depressive symptoms (OR = 1.22, p = 0.025, 18 




Structural brain differences at age 14 predate the development of DEBs and depressive 1 
symptoms 2 
Whole brain VBM analyses demonstrated that binge-eating developers had higher GMVs in a 3 
subcortical cluster comprising the right putamen and globus pallidus at age 14 (Figure 1A & 4 
Supplemental Table S6). Conversely, purging developers had lower GMVs in a cluster 5 
encompassing the medial OFC (mOFC), the gyrus rectus, the anterior and middle cingulate 6 
cortex (ACC and MCC), the left dorsomedial and dorsolateral prefrontal cortex (Figure 1B). 7 
Similarly, BoP developers had smaller GMVs at age 14 in the mOFC, gyrus rectus, ACC and MCC 8 
(Figure 1C). No significant GMV differences were associated with dieting developers, “any DEB” 9 
developers, BoP maintainers or BoP recoverers. Repeating analyses by controlling for BMI at 10 
age 14, or removing participants who took any medication in the past 30 days, or removing 11 
individuals reporting other DEBs at age 14 did not substantially change main associations (see 12 
Supplemental Results, Tables S6-S7 & Figures S3-S4). However, repeating the VBM analyses in 13 
girls only did not yield significant results on the whole brain level. 14 
 15 
We tested if brain regions associated with DEB development were also associated with 16 
developing symptoms of depression or generalized anxiety. Whole brain VBM analyses 17 
demonstrated that depression developers had lower GMVs in two clusters comprising the 18 
medial and left lateral OFC, ACC, MCC, the supplementary motor area, the dorsomedial PFC 19 
and left dorsolateral PFC (Figure 1D & Supplemental Table S8). These clusters overlapped with 20 
those associated with purging development in the ACC, MCC, mOFC, dorsomedial and left 21 
 
19 
dorsolateral PFC (Figure 1E). Similar overlaps were found for brain regions associated with 1 
development of BoP and depressive symptoms (Figure 1F). No significant results were found 2 
for the development of anxiety on the whole-brain level.  3 
 4 
Brain structure underlying CD and ADHD symptoms mediate the development of purging and 5 
comorbid depressive symptoms 6 
The analyses presented above suggested that neural correlates of SDQ traits – should they be 7 
detected – may serve as potential brain-based mediators for DEBs. To test this, we first 8 
analyzed associations between GMVs and DEB-associated SDQ measures at age 14, using the 9 
whole sample of 1594 participants. Higher CD symptoms were associated with lower grey 10 
matter volumes in the ACC, mOFC and the superior and middle frontal gyrus (Figure 2A & 11 
Supplemental Table S6). The ACC/mOFC region partly overlapped with those associated with 12 
purging development (262 voxels), BoP development (59 voxels) and depression development 13 
(74 voxels, Figure 2A). In contrast, higher ADHD symptoms were significantly associated with 14 
lower GMVs in a cluster encompassing the mOFC, gyrus rectus and anterior orbital gyrus 15 
(Figure 2B & Supplemental Table S6). These regions overlapped with those associated with 16 
purging development (461 voxels), BoP development (853 voxels) and depression 17 
development (148 voxels, Figure 2B). No significant GMV associations were observed for 18 




Next, we investigated whether the GMV differences identified above mediated the relationship 1 
between CD or ADHD symptoms at age 14 and the development of purging, BoP and 2 
depression. Brain regions associated with CD symptoms (ACC/mOFC) and ADHD symptoms 3 
(labelled as OFC) were used as ROIs. Lower GMVs in the ACC/mOFC mediated the relationship 4 
between CD symptoms and the development of purging (indirect effect = 0.021, bootstrap 95% 5 
CI = 7.3E-04-0.056) and depression (indirect effect = 0.021, bootstrap 95% CI = 0.0023-0.050, 6 
Figure 3A). Likewise, lower GMVs in the OFC mediated the association between ADHD 7 
symptoms and the development of purging (indirect effect = 0.024, bootstrap 95% CI = 0.0016-8 
0.058) and depression (indirect effect = 0.025, bootstrap 95% CI = 0.0039-0.053, Figure 3B). 9 
Similarly, these ROIs significantly mediated the effects of CD and ADHD symptoms on the 10 
development of BoP (Supplemental Figure S5). No significant mediation effects were found for 11 




Our longitudinal analyses, aimed at identifying early predictors of the development of DEBs 2 
and comorbid depression/anxiety symptoms in adolescence, identified shared neural 3 
substrates underlying the psychopathological risk for the development of DEBs and depression. 4 
We show that higher GMVs in the putamen and globus pallidus and emotional difficulties 5 
predate the development of binge-eating. We similarly demonstrated that lower GMVs in 6 
frontal and cingulate cortices, and ADHD and CD symptoms were associated with development 7 
of purging, BoP and depression. Importantly, the lower GMVs associated with ADHD and CD 8 
symptoms mediated the relationships between these symptoms and future purging, BoP and 9 
depression. These results support previous research showing high prevalence of ADHD, CD, 10 
depression and GAD in EDs, particularly in bulimia nervosa (7, 8), and extend our knowledge of 11 
the neural underpinning of these disorders.  12 
 13 
We have identified several neural substrates as early markers for the development of DEBs. 14 
Lower GMVs across the prefrontal cortex, including the mOFC, ACC, MCC, the dorsomedial 15 
and dorsolateral PFC are early indicators for the development of purging and BoP behaviors. 16 
Our mediation analyses also implicate the OFC and ACC/mOFC in the neural mechanisms 17 
underlying the associations between ADHD and CD symptoms and future purging and BoP 18 
behaviors. These results are consistent with previous suggestions of overlapping neural circuits 19 
involved in cognitive control and reward systems between ADHD and EDs (35). For example, 20 
 
22 
reduced GMVs in the OFC are consistently found in ADHD patients (36), which correlate with 1 
their functional impairments in emotion regulation, reward-related decision making and 2 
control of motivation (37). Shared neurobiological mechanisms (35) are further supported by 3 
observations of overlapping treatment responses to psychostimulant medications in ADHD and 4 
BN/BED patients (38, 39). 5 
 6 
Youths with ADHD are at higher risk of developing depression (40), and their common 7 
neurobiological mechanisms have been suggested (41). For example, resting-state functional 8 
connectivity between the left OFC and left hippocampus is reduced in children with ADHD; 9 
furthermore, this connectivity is also negatively associated with depressive symptom severity in 10 
children with ADHD (41). However, research on neurobiological mechanisms of ADHD and 11 
depression has been largely separate, and the neural mediators between the two have been 12 
unclear until now. Our results highlight structural differences in the OFC to be a neural substrate 13 
that confers higher risk for depression in youths with greater ADHD symptoms. As the OFC plays 14 
important roles in emotion regulation (42), our result concurs with the finding that emotion 15 
regulation deficiencies mediate the association between ADHD and depressive symptoms (43, 44). 16 
By demonstrating that reduced GMVs in the OFC mediate the effect of ADHD symptoms on both 17 
future purging and depressive symptoms, our results further suggest that ADHD, depression and 18 




The observed reduced GMVs in the ACC/mOFC was consistent with recent neuroimaging 1 
findings in CDs (45). Both the ACC and mOFC are involved in reward-based decision making by 2 
encoding action-reward associations (46, 47) and also in top-down emotion regulation (48). 3 
Our results suggest that impairments in reward processing and/or emotion regulation may 4 
underlie the link between conduct problems and future purging behaviors and depression. 5 
 6 
Other brain regions associated with purging/BoP symptoms, i.e., the dorso-lateral, dorso-7 
medial PFC and ACC, are part of the inhibition control system responsible for regulatory control 8 
and response inhibition (49). Hypoactivation of these regions has been associated with 9 
substance use and behavioral addictions (49). In line with our findings, a cluster in the ACC was 10 
also found by Bartholdy et al. (2019) to be hypo-activated in BoP developers during successful 11 
(vs. failed) response inhibition (23). Conversely, activating the dorsolateral PFC with high-12 
frequency repetitive transcranial magnetic stimulation (rTMS) can reduce food craving and 13 
binge-eating frequencies in bulimic disorders (50). Based on these findings, lower GMVs in the 14 
dorsolateral and dorsomedial PFC in purging developers suggest weakened functions in 15 
inhibition control, which may underlie their vulnerability to impulsive behaviors like purging. 16 
 17 
The neural substrates associated with development of binge-eating encompassed the right 18 
putamen and globus pallidus, with greater GMVs implicating higher risk. Previous studies of ED 19 
patients found reduced GMVs in the bilateral striatum in BN (18) and BED (51, 52) and 20 
increased GMVs in the OFC for BN (18), which is at odds with our findings. The differences may 21 
 
24 
be due to sample characteristics and the study design, previous neuroimaging studies being 1 
cross-sectional and involving adult patients with EDs. In comparison, the present study 2 
investigated onset of DEBs symptoms in a longitudinal cohort of healthy adolescents. It is 3 
possible that higher putamen volumes confer risk for future binge-eating, while reduced 4 
volumes ensue from suffering these conditions over the years. Clearly, more longitudinal 5 
developmental research is needed to study abnormal developmental patterns associated with 6 
DEBs and depression.  7 
 8 
Strengths and Limitations 9 
Our study has several strengths. First, it is one of the only two longitudinal studies (23) to 10 
examine the neurobiological predictors of DEBs in a well-characterized population-based 11 
adolescent cohort. The sample size and multi-modality of the data (questionnaires and 12 
neuroimaging) were other strengths of our study. Matching sex and acquisition sites between 13 
case and control groups removed confounding effects from these variables. 14 
 15 
There are also several weaknesses to consider. First, the very limited number of males in the 16 
case groups did not enable us to investigate sex-specific effects. Second, the effects of other 17 
confounding factors (e.g., parental and social) were not ruled out. Thirdly, DEBs were assessed 18 
through self-reports only. Fourthly, it cannot be concluded that the risk factors identified here 19 
are associated exclusively with a single DEB as our analyses did not exclude coexisting DEBs. 20 
Fifth, the mediation analysis included two variables (SDQ symptoms and brain structure) 21 
 
25 
assessed at one time point and a third variable (development of DEB or depression) assessed 1 
at another, rather than all variables assessed at separate time points. Lastly, as we we did not 2 
find significant structural brain risk factors for dieting, the neurobiological risk factors for 3 
restrictive eating behaviors remain unclear (53).  4 
 5 
Overall, our study highlights psychopathological traits that may be causal risk factors of DEBs, 6 
including emotional problems, ADHD and CD symptoms, which can help identify high-risk 7 
groups for targeted prevention. The identification of neurobiological substrates of DEBs and 8 
comorbid depression, specifically in the OFC and ACC, provides promising therapeutic 9 
strategies for EDs and comorbid conditions (54, 55). 10 
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Figure Legends 1 
FIGURE 1. Structural brain associations with the development of binge-eating (A), purging (B), 2 
binge-eating or purging (BoP, C) and depressive symptoms (D). The bar plots show the regional 3 
means of GMVs, adjusted by sex, acquisition site and total intracranial volumes. Error bars 4 
represent standard errors. Statistical parametric maps were thresholded at voxel-level p<0.001 5 
(uncorrected) and cluster-level p<0.05 (FWE corrected). Overlapping brain regions associated 6 
with the development of purging and depressive symptoms are presented in E. Overlapping 7 
brain regions for the development of BoP and depressive symptoms are presented in F. The 8 
3D rendered views are generated by MRIcroGL 9 
(https://www.mccauslandcenter.sc.edu/mricrogl/). 10 
 11 
FIGURE 2. Grey matter volume associations with CD symptoms (A, negative association) and 12 
ADHD symptoms (B, negative association) at age 14. Statistical parametric maps were 13 
thresholded at voxel-level p<0.001 (uncorrected) and cluster-level p<0.05 (FWE corrected). 14 
The columns to the right show overlapping brain regions associated with the development of 15 
purging, BoP and depressive symptoms. 16 
 17 
FIGURE 3. Results for the mediation analysis, using the ACC/mOFC ROI linked to CD symptoms 18 
(A) and the OFC ROI linked to ADHD symptoms (B) as mediators. For analyses on the 19 
development of purging, control variables included sex, acquisition sites and the total 20 
 
39 
intracranial volume. For analyses on the development of depression (blue dashed lines), the 1 
depression symptom at age 14 was involved as an additional control variable. ROI: region of 2 









SDQ symptoms at age 14 
Without controlling for BMI After controlling for BMI 





conduct problems 1.29 1.06-1.57 1.1E-02    
emotional symptoms 1.35 1.10-1.66 4.4E-03 1.34 1.09-1.65 5.7-03 
hyperactivity/ inattention 1.27 1.03-1.57 2.4E-02    





conduct problems 1.43 1.20-1.71 8.5E-05 1.41 1.18-1.70 1.5E-04 
emotional symptoms 1.24 1.03-1.49 2.5E-02    
hyperactivity/inattention 1.35 1.12-1.64 1.6E-03 1.37 1.13-1.66 1.2E-03 





conduct problems 1.22 0.92-1.59 1.6E-01    
emotional symptoms 1.22 0.91-1.63 1.8E-01    
hyperactivity/inattention 1.17 0.88-1.57 2.7E-01    
peer problems 1.23 0.94-1.59 1.2E-01    
The p values shown in bold survived the Holm-Bonferroni correction, correcting for 12 tests (3 DEBs × 3 
4 SDQ subscales). Significant associations were further controlled for BMI. DEB: disordered eating 4 
behavior. 5 
 6 




Table 2. Psychopathological predictors for the development of depression and generalized 2 







Controlling for the 
corresponding mental health 
symptom at age 14 
Additionally controlling for 
the other mental health 
symptom at all ages 
OR 95% CI P OR 95% CI P 
Depression hyperactivity/ 
inattention 
1.25  1.08-1.44 2.5E-03 1.10  0.93-1.29  0.27 
conduct 
problems 
1.32  1.13-1.54  4.6E-04 1.22  1.03-1.46  0.025 
emotional 
symptoms 





1.33  1.13-1.57  5.4E-04 1.24  1.00-1.53  0.045 
conduct 
problems 
1.26  1.06-1.49  9.3E-03 0.97  0.77-1.22  0.79 
emotional 
symptoms 
1.79  1.46-2.19  1.0E-08 1.56  1.22-2.00  3.7E-04 
The p values shown in bold survived the Holm-Bonferroni correction, correcting for 6 tests (2 mental 4 
health symptoms × 3 SDQ subscales). Significant associations were further controlled for the other 5 
mental health symptom at ages 14, 16 and 19 (i.e., controlling depression development for anxiety 6 
symptoms at all ages, and vice-versa).  7 
 8 
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 10 
